DNA methylation patterns may explain why some prostate cancers turn lethal

The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...

Veracyte Stock Surges 117% in a Year: What's Driving the Rally?

VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a ...
Hosted on MSN

This top stock has surged. CEO explains key to Veracyte's success.

VeracyteVCYT opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. In fact, for some, these treatments could make their outcomes worse. Today, the South San ...

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

How much a stock's price changes over time is important for most investors, since price performance can both impact your ...

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Learn more Jonathan Wygant, Vice President and Chief Accounting Officer of Veracyte (NASDAQ:VCYT), reported the exercise of ...
The Motley Fool

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Veracyte offers genomic diagnostic tests for cancer and other diseases, including Afirma, Decipher, Prosigna, Percepta, Envisia, and Immunoscore, with a focus on thyroid, prostate, breast, lung, and ...
UroToday

APCCC 2026: Can Genomics/Artificial Intelligence Help to Minimize Over- or Undertreatment?

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a high-risk and locally advanced prostate cancer session and a presentation by Dr. Jason Efstathiou ...